Ionic Liquid-mediated Delivery of a BCL-2 Inhibitor for Topical Treatment of Skin Melanoma

Overview

Journal J Control Release

Specialty Pharmacology

Date 2022 Jul 31

PMID 35908622

Authors

Md Nurul Huda

Isaac G Deaguero

Edgar A Borrego

Raj Kumar

Tamanna Islam

Humayra Afrin

Armando Varela-Ramirez

Renato J Aguilera

Eden E L Tanner

Md Nurunnabi

Affiliations

Soon will be listed here.

Abstract

Skin melanoma is one of the most common cancer types in the United States and worldwide, and its incidence continues to grow. Primary skin melanoma can be removed surgically when feasible and if detected at an early stage. Anti-cancer drugs can be applied topically to treat skin cancer lesions and used as an adjunct to surgery to prevent the recurrence of tumor growth. We developed a topical formulation composed of Navitoclax (NAVI), a BCL-2 inhibitor that results in apoptosis, and an ionic liquid of choline octanoate (COA) to treat early-stage melanoma. NAVI is a small hydrophobic molecule that solubilizes at 20% (w/v) when dissolved in 50% COA. Although NAVI is a highly effective chemotherapeutic, it is equally thrombocytopenic. We found that COA-mediated topical delivery of NAVI enhanced its penetration into the skin and held the drug in the deeper skin layers for an extended period. Topical delivery of NAVI produced a higher cancer-cell killing efficacy than orally administrated NAVI. In vivo experiments in a mouse model of human melanoma-induced skin cancer confirmed the formulation's effectiveness via an apoptotic mechanism without any significant skin irritation or systemic absorption of NAVI. Overall, this topical approach may provide a safe and effective option for better managing skin cancer in the clinic.

Citing Articles

Design Principles and Applications of Ionic Liquids for Transdermal Drug Delivery.

Gao S, Cheng X, Zhang M, Dai Q, Liu C, Lu Y Adv Sci (Weinh). 2024; 11(43):e2405983.

PMID: 39342651 PMC: 11578336. DOI: 10.1002/advs.202405983.

Synthesis, Characterisation, and In Vitro Evaluation of Biocompatibility, Antibacterial and Antitumor Activity of Imidazolium Ionic Liquids.

Novello E, Scalzo G, DAgata G, Raucci M, Ambrosio L, Soriente A Pharmaceutics. 2024; 16(5).

PMID: 38794304 PMC: 11125126. DOI: 10.3390/pharmaceutics16050642.

Ionic liquids as the effective technology for enhancing transdermal drug delivery: Design principles, roles, mechanisms, and future challenges.

Chen X, Li Z, Yang C, Yang D Asian J Pharm Sci. 2024; 19(2):100900.

PMID: 38590797 PMC: 10999516. DOI: 10.1016/j.ajps.2024.100900.

Potentials of ionic liquids to overcome physical and biological barriers.

Beaven E, Kumar R, An J, Mendoza H, Sutradhar S, Choi W Adv Drug Deliv Rev. 2023; 204:115157.

PMID: 38104896 PMC: 10787599. DOI: 10.1016/j.addr.2023.115157.

Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy.

Neill B, Romero A, Fenton O ACS Appl Bio Mater. 2023; 7(8):4894-4913.

PMID: 37930174 PMC: 11220486. DOI: 10.1021/acsabm.3c00721.

References

Nurunnabi M, Ibsen K, Tanner E, Mitragotri S . Oral ionic liquid for the treatment of diet-induced obesity. Proc Natl Acad Sci U S A. 2019; 116(50):25042-25047. PMC: 6911186. DOI: 10.1073/pnas.1914426116. View

Lens M, Dawes M . Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004; 150(2):179-85. DOI: 10.1111/j.1365-2133.2004.05708.x. View

Demartis S, Rassu G, Murgia S, Casula L, Giunchedi P, Gavini E . Improving Dermal Delivery of Rose Bengal by Deformable Lipid Nanovesicles for Topical Treatment of Melanoma. Mol Pharm. 2021; 18(11):4046-4057. PMC: 8564756. DOI: 10.1021/acs.molpharmaceut.1c00468. View

Certo M, Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong S . Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006; 9(5):351-65. DOI: 10.1016/j.ccr.2006.03.027. View

Leverson J, Phillips D, Mitten M, Boghaert E, Diaz D, Tahir S . Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015; 7(279):279ra40. DOI: 10.1126/scitranslmed.aaa4642. View

Xiong H, Pradhan R, Nada A, Krivoshik A, Holen K, Rhodes J . Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014; 34(7):3739-46. View

Garcia-Saez A . The secrets of the Bcl-2 family. Cell Death Differ. 2012; 19(11):1733-40. PMC: 3469065. DOI: 10.1038/cdd.2012.105. View

Sharma A, Roberts R, Benson Jr R, Pierce J, Yu K, Hamrick M . The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice. Front Cell Dev Biol. 2020; 8:354. PMC: 7252306. DOI: 10.3389/fcell.2020.00354. View

Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, van Oers M . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84(5):1415-20. View

10.

Montero J, Letai A . Why do BCL-2 inhibitors work and where should we use them in the clinic?. Cell Death Differ. 2017; 25(1):56-64. PMC: 5729538. DOI: 10.1038/cdd.2017.183. View

11.

de Marcos S, Galban J, Alonsa C, Castillo J . Intrinsic molecular fluorescence of lactate dehydrogenase: an analytical alternative for enzymic determination of pyruvate. Analyst. 1997; 122(4):355-9. DOI: 10.1039/a606508b. View

12.

Loyal J, Romano M, Pierson J . Exuberant inflammatory reaction to occlusion of topical 5-fluorouracil (FU) under a continuous positive airway pressure (CPAP) mask: A warning to dermatologists and patients. JAAD Case Rep. 2016; 2(3):278-80. PMC: 4949501. DOI: 10.1016/j.jdcr.2016.05.011. View

13.

Monti D, Egiziano E, Burgalassi S, Chetoni P, Chiappe C, Sanzone A . Ionic liquids as potential enhancers for transdermal drug delivery. Int J Pharm. 2016; 516(1-2):45-51. DOI: 10.1016/j.ijpharm.2016.11.020. View

14.

Jiang T, Wang T, Li T, Ma Y, Shen S, He B . Enhanced Transdermal Drug Delivery by Transfersome-Embedded Oligopeptide Hydrogel for Topical Chemotherapy of Melanoma. ACS Nano. 2018; 12(10):9693-9701. DOI: 10.1021/acsnano.8b03800. View

15.

Robles-Escajeda E, Lerma D, Nyakeriga A, Ross J, Kirken R, Aguilera R . Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells. PLoS One. 2013; 8(9):e73508. PMC: 3767772. DOI: 10.1371/journal.pone.0073508. View

16.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

17.

Christensen S . Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. F1000Res. 2018; 7. PMC: 5989149. DOI: 10.12688/f1000research.12837.1. View

18.

Yu M, Li X, Liang R, Yang J, Zhang Y, Wang H . A new ligand of CD105 screened out by phage display technology provides a reliable identification of recurrent or metastasizing pleomorphic adenoma from pleomorphic adenoma. Int Immunopharmacol. 2018; 65:37-43. DOI: 10.1016/j.intimp.2018.09.042. View

19.

Flieger J, Flieger M . Ionic Liquids Toxicity-Benefits and Threats. Int J Mol Sci. 2020; 21(17). PMC: 7504185. DOI: 10.3390/ijms21176267. View

20.

Smith D, Simon J, Baker Jr J . Applications of nanotechnology for immunology. Nat Rev Immunol. 2013; 13(8):592-605. PMC: 7097370. DOI: 10.1038/nri3488. View